Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer

Cancer

Volumn 74, Issue 8, 1994, Pages 2276-2280

  Duffy, Michael J ^a   Reilly, David ^a   McDermott, E ^a   O'Higgins, Niall ^a   Fennelly, James J ^a   Andreasen, Peter A ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

breast cancer; prognosis; protease; urokinase plasminogen activator

Indexed keywords

APROTININ; EDETIC ACID; ESTROGEN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; SERINE PROTEINASE; TRITON X 100; TROMETAMOL; UROKINASE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ANIMAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHATIC METASTASIS; MIDDLE AGE; PROGNOSIS; RECEPTORS, ESTROGEN; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028114470     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19941015)74:8<2276::AID-CNCR2820740811>3.0.CO;2-7     Document Type: Article

References (30)

1. Role of proteolytic enzymes in cancer invasion and metastasis
2. Molecular aspects of lumor cell invasion and metastasis
3. Urokinase plasminogen activator and malignancy
4. Endogenous activation of latent collagenase by rheumatoid cells
5. Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines
6. Proteolytic enzymes in tumor metastasis. 1. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma
7. Involvement of plasminogen activator production with tumor metastasis in a rat model
8. Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells
9. Inhibition of cancer cell urokinase by its specific inhibitor PAI‐2 and subsequent effects on extracellular matrix degradation
10. Antibodies to plasminogen activator inhibit human tumor metastasis
11. Expression of human recombinant plasminogen activator enhances invasion and experimental metastasis of H‐ras‐transformed NIH 3T3 cells
12. Mouse L‐cells expressing human prourokinasetype plasminogen activator: effects on extracellular matrix degradation and invasion
13. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes
14. Urokinase plasminogen activator, a marker for aggressive breast cancers. Preliminary report
15. Urokinase plasminogen activator in breast cancer
16. 1990, Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer
17. Urokinase‐type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer
18. Urokinase plasminogen activator (uPA) and its inhibitor PAI‐1 are strong and independent prognostic factor in node‐negative breast cancer
19. Prognostic value of urokinase‐type plasminogen activator in 671 primary breast cancer patients
20. High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
21. CEA‐like concentrations in cytosols from human breast carcinomas
22. Cathepsin D: an independent prognostic factor for metastasis of breast cancer
23. Cathepsin D and prognosis in breast cancer
24. Cathepsin D concentration in breast cancer cytosols: correlation with overall survival
25. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol
26. Cellular oncogenes and suppressor genes as prognostic markers, a review
27. Prognostic relevance of mucosal plasminogen activator levels in colorectal cancer
28. The content of urokinase‐type plasminogen activator as a prognostic factor in bladder cancer
29. Immunohistochemical evidence of urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma
30. Tumor‐associated proteolytic factors uPA and PAI‐1 and survival in totally resected gastric cancer